Evidence map›Paper›PMID 25988387›Full record

ArticleInternational journal of molecular sciences2015

Serum amyloid A receptor blockade and incorporation into high-density lipoprotein modulates its pro-inflammatory and pro-thrombotic activities on vascular endothelial cells.

Belal Chami, Nicola Barrie, Xiaoping Cai, Xiaosuo Wang, Moumita Paul, Rebecca Morton-Chandra, Alexandra Sharland, Joanne M Dennis, Saul B Freedman, Paul K Witting

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Serum amyloid A in HFpEF and cardiometabolic diseases.Basic research in cardiology · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Role of serum amyloid A in atherosclerosis.Current opinion in lipidology · 2019
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Belal ChamiDiscipline of Pathology, Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia. belal.chami@sydney.edu.au.
Nicola BarrieDiscipline of Pathology, Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia. nicola.gbarrie@gmail.com.
Xiaoping CaiDiscipline of Pathology, Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia. xcai4874@uni.sydney.edu.au.
Xiaosuo WangDiscipline of Pathology, Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia. xiaosuo.wang@sydney.edu.au.
Moumita PaulTransplantation Immunobiology Group, Central Clinical School, Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia. moumita.paul@sydney.edu.au.
Rebecca Morton-ChandraTransplantation Immunobiology Group, Central Clinical School, Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia.
Alexandra SharlandTransplantation Immunobiology Group, Central Clinical School, Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia. alexandra.sharland@sydney.edu.au.
Joanne M DennisDiscipline of Pathology, Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia. martindennis@optusnet.com.au.
Saul B FreedmanSydney Medical School, the University of Sydney, ANZAC Research Institute, Concord Repatriation General Hospital, Sydney, NSW 2139, Australia. ben.freedman@sydney.edu.au.
Paul K WittingDiscipline of Pathology, Sydney Medical School, the University of Sydney, Sydney, NSW 2006, Australia. paul.witting@sydney.edu.au.
The University of Sydney · AUConcord Repatriation General Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The acute phase protein serum amyloid A (SAA), a marker of inflammation, induces expression of pro-inflammatory and pro-thrombotic mediators including ICAM-1, VCAM-1, IL-6, IL-8, MCP-1 and tissue factor (TF) in both monocytes/macrophages and endothelial cells, and induces endothelial dysfunction-a precursor to atherosclerosis. In this study, we determined the effect of pharmacological inhibition of known SAA receptors on pro-inflammatory and pro-thrombotic activities of SAA in human carotid artery endothelial cells (HCtAEC). HCtAEC were pre-treated with inhibitors of formyl peptide receptor-like-1 (FPRL-1), WRW4; receptor for advanced glycation-endproducts (RAGE), (endogenous secretory RAGE; esRAGE) and toll-like receptors-2/4 (TLR2/4) (OxPapC), before stimulation by added SAA. Inhibitor activity was also compared to high-density lipoprotein (HDL), a known inhibitor of SAA-induced effects on endothelial cells. SAA significantly increased gene expression of TF, NFκB and TNF and protein levels of TF and VEGF in HCtAEC. These effects were inhibited to variable extents by WRW4, esRAGE and OxPapC either alone or in combination, suggesting involvement of endothelial cell SAA receptors in pro-atherogenic gene expression. In contrast, HDL consistently showed the greatest inhibitory action, and often abrogated SAA-mediated responses. Increasing HDL levels relative to circulating free SAA may prevent SAA-mediated endothelial dysfunction and ameliorate atherogenesis.

Indexed as

Apolipoprotein A-ICells, CulturedEndothelial CellsEnzyme-Linked Immunosorbent AssayGene Expression RegulationHumansImmunohistochemistryLipoproteins, HDLNF-kappa BPeptidesPhosphatidylcholinesReceptor for Advanced Glycation End ProductsReceptors, Formyl PeptideReceptors, LipoxinRecombinant ProteinsSerum Amyloid A ProteinApolipoprotein A-IFPR2 protein, humanLipoproteins, HDLNF-kappa Boxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholinePeptidesPhosphatidylcholinesReceptor for Advanced Glycation End ProductsReceptors, Formyl PeptideReceptors, LipoxinRecombinant ProteinsSerum Amyloid A ProteinThromboplastinTumor Necrosis Factor-alphaVascular Endothelial Growth Factor Aatherosclerosishigh-density lipoproteininflammationserum amyloid A

Identifiers

PMID25988387
PMCPMC4463692
OpenAlexW1540202877

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.